SAB Biotherapeutics collaborates with CSL Behring

Clinical-stage US biopharma company SAB Biotherapeutics has entered into multiple collaboration and option agreements with CSL Behring, a blood products and vaccines specialist, which is part of Australia’s CSL Limited (ASX: CSL).

The collaborations will explore the possibility and the potential of new therapies to treat challenging autoimmune, infectious and idiopathic diseases by leveraging SAB’s DiversitAb platform. CSL Behring and SAB will share research program and related costs and plan to complete the initial phase in 2020. The collaboration may lead to subsequent development and commercialization agreements.

SAB has developed a unique platform, through advanced genetic engineering, to naturally and rapidly produce large amounts of human antibodies without using human donors.